| __timestamp | MiMedx Group, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 1499100000 |
| Thursday, January 1, 2015 | 133384000 | 1923500000 |
| Friday, January 1, 2016 | 179997000 | 2351400000 |
| Sunday, January 1, 2017 | 220119000 | 2564000000 |
| Monday, January 1, 2018 | 258528000 | 2397300000 |
| Tuesday, January 1, 2019 | 198205000 | 2503400000 |
| Wednesday, January 1, 2020 | 181022000 | 3344600000 |
| Friday, January 1, 2021 | 198359000 | 4529200000 |
| Saturday, January 1, 2022 | 208789000 | 4179100000 |
| Sunday, January 1, 2023 | 211124000 | 4650100000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. A key indicator of this efficiency is the Selling, General, and Administrative (SG&A) expenses. Over the past decade, Viatris Inc. and MiMedx Group, Inc. have showcased contrasting trends in their SG&A expenditures.
From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, MiMedx Group, Inc. maintained a more modest growth, with expenses rising by about 133% over the same period, reaching around $211 million in 2023.
These figures highlight Viatris's expansive operational scale compared to MiMedx. As the industry continues to evolve, understanding these financial dynamics is crucial for stakeholders aiming to navigate the competitive pharmaceutical market.
Comparing SG&A Expenses: Viatris Inc. vs Summit Therapeutics Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and Insmed Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or Madrigal Pharmaceuticals, Inc.
Viatris Inc. vs Exelixis, Inc.: SG&A Expense Trends
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viatris Inc. and Evotec SE
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and MiMedx Group, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and MiMedx Group, Inc.
Comparing SG&A Expenses: Soleno Therapeutics, Inc. vs MiMedx Group, Inc. Trends and Insights